Evaluation of initial progress to implement Common Metrics across the NIH Clinical and Translational Science Awards (CTSA) Consortium
© The Association for Clinical and Translational Science 2020..
INTRODUCTION: The Clinical and Translational Science Awards (CTSA) Consortium, about 60 National Institutes of Health (NIH)-supported CTSA hubs at academic health care institutions nationwide, is charged with improving the clinical and translational research enterprise. Together with the NIH National Center for Advancing Translational Sciences (NCATS), the Consortium implemented Common Metrics and a shared performance improvement framework.
METHODS: Initial implementation across hubs was assessed using quantitative and qualitative methods over a 19-month period. The primary outcome was implementation of three Common Metrics and the performance improvement framework. Challenges and facilitators were elicited.
RESULTS: Among 59 hubs with data, all began implementing Common Metrics, but about one-third had completed all activities for three metrics within the study period. The vast majority of hubs computed metric results and undertook activities to understand performance. Differences in completion appeared in developing and carrying out performance improvement plans. Seven key factors affected progress: hub size and resources, hub prior experience with performance management, alignment of local context with needs of the Common Metrics implementation, hub authority in the local institutional structure, hub engagement (including CTSA Principal Investigator involvement), stakeholder engagement, and attending training and coaching.
CONCLUSIONS: Implementing Common Metrics and performance improvement in a large network of research-focused organizations proved feasible but required substantial time and resources. Considerable heterogeneity across hubs in data systems, existing processes and personnel, organizational structures, and local priorities of home institutions created disparate experiences across hubs. Future metric-based performance management initiatives across heterogeneous local contexts should anticipate and account for these types of differences.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Journal of clinical and translational science - 5(2020), 1 vom: 28. Juli, Seite e25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Welch, Lisa C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CTSA |
|---|
| Anmerkungen: |
Date Revised 22.04.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1017/cts.2020.517 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325011915 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325011915 | ||
| 003 | DE-627 | ||
| 005 | 20231225191529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/cts.2020.517 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325011915 | ||
| 035 | |a (NLM)33948248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Welch, Lisa C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of initial progress to implement Common Metrics across the NIH Clinical and Translational Science Awards (CTSA) Consortium |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Association for Clinical and Translational Science 2020. | ||
| 520 | |a INTRODUCTION: The Clinical and Translational Science Awards (CTSA) Consortium, about 60 National Institutes of Health (NIH)-supported CTSA hubs at academic health care institutions nationwide, is charged with improving the clinical and translational research enterprise. Together with the NIH National Center for Advancing Translational Sciences (NCATS), the Consortium implemented Common Metrics and a shared performance improvement framework | ||
| 520 | |a METHODS: Initial implementation across hubs was assessed using quantitative and qualitative methods over a 19-month period. The primary outcome was implementation of three Common Metrics and the performance improvement framework. Challenges and facilitators were elicited | ||
| 520 | |a RESULTS: Among 59 hubs with data, all began implementing Common Metrics, but about one-third had completed all activities for three metrics within the study period. The vast majority of hubs computed metric results and undertook activities to understand performance. Differences in completion appeared in developing and carrying out performance improvement plans. Seven key factors affected progress: hub size and resources, hub prior experience with performance management, alignment of local context with needs of the Common Metrics implementation, hub authority in the local institutional structure, hub engagement (including CTSA Principal Investigator involvement), stakeholder engagement, and attending training and coaching | ||
| 520 | |a CONCLUSIONS: Implementing Common Metrics and performance improvement in a large network of research-focused organizations proved feasible but required substantial time and resources. Considerable heterogeneity across hubs in data systems, existing processes and personnel, organizational structures, and local priorities of home institutions created disparate experiences across hubs. Future metric-based performance management initiatives across heterogeneous local contexts should anticipate and account for these types of differences | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTSA | |
| 650 | 4 | |a Common Metrics | |
| 650 | 4 | |a Performance improvement | |
| 650 | 4 | |a clinical and translational science | |
| 650 | 4 | |a evaluation | |
| 700 | 1 | |a Tomoaia-Cotisel, Andrada |e verfasserin |4 aut | |
| 700 | 1 | |a Noubary, Farzad |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Mendel, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Parajulee, Anshu |e verfasserin |4 aut | |
| 700 | 1 | |a Fenwood-Hughes, Marguerite |e verfasserin |4 aut | |
| 700 | 1 | |a Etchegaray, Jason M |e verfasserin |4 aut | |
| 700 | 1 | |a Qureshi, Nabeel |e verfasserin |4 aut | |
| 700 | 1 | |a Chandler, Redonna |e verfasserin |4 aut | |
| 700 | 1 | |a Selker, Harry P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and translational science |d 2017 |g 5(2020), 1 vom: 28. Juli, Seite e25 |w (DE-627)NLM271221658 |x 2059-8661 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2020 |g number:1 |g day:28 |g month:07 |g pages:e25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/cts.2020.517 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2020 |e 1 |b 28 |c 07 |h e25 | ||